Jiaxin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiaxin Li has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Chengjun Liu
Joint International Research Laboratory of Information Display and Visualization, School of Electronic Science and Engineering, Southeast University 1 , Nanjing, China
2 shared publications - Guo Chen
Research Center for Electronic and Optical Materials National Institute for Materials Science Namiki 1‐1 Tsukuba Ibaraki Japan
2 shared publications - Sen Zhang
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2 shared publications - Xiao-Feng Huang
Peking University Shenzhen Graduate School
2 shared publications - Yu Zhang
Department of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China
2 shared publications Huimin Zhou
Department of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (31) , eadx6732
Morphology– and adhesion–dual biomimetic nanovaccine boosts antigen cross-presentation through subcellular transport regulation
In situ tumor vaccines have immense potential for immunotherapy because they generate whole tumor–derived antigens (TDAs) to activate antitumor immune responses. However, the rapid degradation and clearance of the released TDAs severely hinder subsequent antigen presentation and the final efficacy of the in situ vaccine. Here, we synthesized gold nanoxanthium coated with polydopamine (AuNX-PDA) to mimic the morphological and biological adhesion properties of xanthium and mussels, respectively. AuNX-PDA facilitated effective absorption of released TDAs after near-infrared II photothermal treatment and delivery of the absorbed TDAs to the endoplasmic reticulum and Golgi apparatus of dendritic cells for cross-presentation, thereby activating CD8 + T cells for efficient tumor-specific immunity. The nanovaccine (NV) significantly inhibited irradiated primary tumors and nonirradiated distant tumors by producing robust antitumor immune responses in B16F10 melanoma and 4T1 breast cancer mouse models. These findings highlight the potency of morphology– and adhesion–dual biomimetic NVs in whole-tumor vaccine therapy.
- 1 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (31) , eadx6732
Open AccessMorphology– and adhesion–dual biomimetic nanovaccine boosts antigen cross-presentation through subcellular transport regulation
In situ tumor vaccines have immense potential for immunotherapy because they generate whole tumor–derived antigens (TDAs) to activate antitumor immune responses. However, the rapid degradation and clearance of the released TDAs severely hinder subsequent antigen presentation and the final efficacy of the in situ vaccine. Here, we synthesized gold nanoxanthium coated with polydopamine (AuNX-PDA) to mimic the morphological and biological adhesion properties of xanthium and mussels, respectively. AuNX-PDA facilitated effective absorption of released TDAs after near-infrared II photothermal treatment and delivery of the absorbed TDAs to the endoplasmic reticulum and Golgi apparatus of dendritic cells for cross-presentation, thereby activating CD8 + T cells for efficient tumor-specific immunity. The nanovaccine (NV) significantly inhibited irradiated primary tumors and nonirradiated distant tumors by producing robust antitumor immune responses in B16F10 melanoma and 4T1 breast cancer mouse models. These findings highlight the potency of morphology– and adhesion–dual biomimetic NVs in whole-tumor vaccine therapy.